ReviewActa dermato-venereologica2020
A New Generation of Treatments for Itch.
Review in Acta dermato-venereologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.American journal of clinical dermatology · 2023Trial
- Cross-Talk between Neurons and Immune Cells in Pruritus: from Mechanisms To Medicines.Current allergy and asthma reports · 2026Review
- The peripheral neuroimmune system.Journal of leukocyte biology · 2024Review
- Induction of Semaphorin 3A by Resveratrol and Pinostilbene via Activation of the AHR-NRF2 Axis in Human Keratinocytes.Antioxidants (Basel, Switzerland) · 2024Article
- Trisubstituted 1,3,5-Triazines as Histamine HMolecules (Basel, Switzerland) · 2023Article
- Endogenous Opioid Imbalance as a Potential Factor Involved in the Pathogenesis of Chronic Kidney Disease-Associated Pruritus in Dialysis Patients.Journal of clinical medicine · 2023Article
- Uremic pruritus: pathophysiology, clinical presentation, and treatments.Kidney research and clinical practice · 2023Article
- The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers.Life (Basel, Switzerland) · 2022Review
- Role of kappa-opioid and mu-opioid receptors in pruritus: Peripheral and central itch circuits.Experimental dermatology · 2022Article
- Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments.Dermatology and therapy · 2022Review
- Autoimmune Connective Tissue Diseases-Related Pruritus: Proper Diagnosis and Possible Mechanisms.Diagnostics (Basel, Switzerland) · 2022Review
- Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications.JAAD international · 2022Article
- Why Do Patients in the United States Seek Care from Dermatologists?Dermatology and therapy · 2022Article
- Generalized resistance to pruritogen-induced scratching in the C3H/HeJ strain.Frontiers in molecular neuroscience · 2022Article
- Ode to Salt: Commentary on "Skin Sodium Accumulates in Psoriasis and Reflects Disease Severity".The Journal of investigative dermatology · 2022Article
- Influence of Janus Kinase Inhibitors on the Neuronal Activity as a Proof-of-Concept Model for Itch.Skin pharmacology and physiology · 2022Article
- Prurigo Simplex or "Itchy Red Bump" Disease: Review and Case Series.Acta dermato-venereologica · 2021Review
- Molecular and Cellular Mechanisms of Itch in Psoriasis.International journal of molecular sciences · 2020Review
- [Therapy for chronic pruritus-light at the end of a long tunnel?]Der Internist · 2020Review
- [Modern systemic therapy for pruritus].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For decades, antihistamines have been the mainstay of treatment for chronic pruritus, yet they often only work by making patients drowsy and forgetful of their itch. A new era of antipruritic drugs is quickly approaching, presenting more effective treatments for patients suffering from chronic itch. Several treatments have been developed targeting specific receptors in the nervous system, such as the transient receptor potential channels, sodium channels, neurokinin-1 receptors, opioid receptors, and many more. Additionally, antipruritic therapies developed to work on the immune system have become more targeted, leading to greater safety and efficacy measures. These include crisaborole, several interleukin antagonists, and janus kinase inhibitors. The promising results presented with these new antipruritic therapies allow physicians to be better equipped to treat their itchy patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.